Advertisements
Feeds:
Posts
Comments

Archive for the ‘LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management’ Category


e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Author and Editor-in-Chief: Aviva Lev-Ari, PhD RN

 

In this article I cover the Business Synopsis and the following Four Parts of the Business:

Part 1: The Vision

Part 2: Scientific Journal – Site Statistics on 6/20/2017

Part 3: BioMed e-Series

Part 4: Real Time Coverage of 50 Biotech Top Conferences

 

 

Synopsis

  • Interdisciplinary Journal covers interfaces of six domains

(Life sciences, Pharmaceuticals, Medicine, Healthcare Policy, Biotech Intelligence and Medical Devices)

  • Curations of Scientific Findings of peer reviewed articles in top three journals in each of the Six domain
  • Curations written on a multi-Authoring platform by MDs, MD/PhDs, PharmD and PhDs, all 15 years after graduation of the advanced degree program, and each has a publication list before joined my team – they write clinical and medical interpretations of the scientific frontier as evidenced in the Scientific Finding section of published articles in Cell, Nature, Science, NEJM, other top journals in these six domains.
  • Volume, ~5,150 Scientific articles, +500 categories of Research defining the Journal Ontology, 9,500 tags, 7,300, scientific comment on the articles submitted and exchange recorded between the Scientific community and our Team members
  • top two articles >25,000 eReaders
  • Clicks on two Top Authors: >551,000
  • from NIH +3,700 hits
  • 2250 Journal subscribers by e-mail
  • +6,200 Biotech Executive following up on LinkedIn
  • BioMed e-Series: 16 volumes, 9 on Amazon.com

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

  • In House Developed Methodology for Real Time Press Coverage of Biotech Top International conferences – selective  topics covered at conferences lead to NEW Curations in the Journal

 

Part 1: The Vision

https://pharmaceuticalintelligence.com/vision/

Part 2: Scientific Journal – Site Statistics on 6/20/2017

https://pharmaceuticalintelligence.com/

1.3 Million eReaders on WordPress.com in 6/2017

Best ever daily views

2,508 views

Our DOMAINS in Scientific Media

I.  Pharmaceutical: Biologics, Small Molecules, Diagnostics

II.  Life Sciences: Genomics and Cancer Biology

III.  Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology: Metabolomics, Immunology

IV. Biomedicine, BioTech, and MedTech (Medical Devices)

V.  HealthCare: Patient-centered Medicine and Personalized/Precision Medicine

 

All time

1,236,276 eReaders 

2,243 Subscribers by e-mail

7,270 Scientific comments

5,126 Scientific Articles

577 Categories of Research – Journal Ontology

9,591 Tags

Followers (includes Publicize)

790 Twitter

699 Facebook

67 Tumblr

Top Posts >3,000 Views for all days ending 2017-06-20 (Summarized)

Top Authors for all days ending 2017-06-20 (Summarized)

Author Views
Aviva Lev-Ari, PhD RN 322,313
Larry H Bernstein, MD, FCAP 226,768
Tilda Barliya, PhD 48,229
Stephen J Williams, PhD 40,966
Dror Nir, PhD 24,975
Sudipta Saha, PhD 22,713
Ritu Saxena, PhD 15,448
Demet Sag, Ph.D., CRA, GCP 13,315
Aviral Vatsa, PhD 8,132
Ziv Raviv, PhD 7,649
zs22 3,874
Gail S Thornton, MA, PhD(c) 3,535
Anamika Sarkar, PhD 3,280
Danut Dragoi, PhD 2,746
Prabodh Kandala, PhD 2,118
Alan F. Kaul, PharmD., MS, MBA, FCCP 2,065
Aashir Awan, PhD 1,865
Justin D Pearlman, MD, PhD, FACC 1,467
Meg Baker, PhD 1,447
Irina Robu, PhD 969
S. Chakrabarti, Ph.D. 641
Ed Kislauskis, PhD 585
Howard Donohue, PhD 537
David Orchard-Webb, PhD 465
Evelina Cohn, PhD 371
Stuart Cantor, PhD 368
Marzan Khan, BSc – Research Associate 355
apreconasia, DVM 342
Jukka Karjalainen, MD, PhD 229
anayou1, PhD 224
Sreedhar Tirunagari, PhD 158
gerag2015, ESQ 112
Larry Mulligan , PhD 91
Kelly Perlman, BSc (c) Research Associate 66
Rosalind Codrington, PhD 32

Graphics for 4/2012 to 3/10/2015

Part 3: BioMed e-Series

  • The Methodology of Co-Curation


Image Source: Original Conceptualization of the Co-Curation Concept by Stephen J Williams, 3/10/2015

Titles in the BioMed e-Series: 16 e-Books in Medicine and Life Sciences

https://www.amazon.com/s/ref=dp_byline_sr_ebooks_9?ie=UTF8&text=Aviva+Lev-Ari&search-alias=digital-text&field-author=Aviva+Lev-Ari&sort=relevancerank

9 results for Kindle Store : “Aviva Lev-Ari”

  • Product Details

    Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

    Nov 28, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)

    May 13, 2017 | Kindle eBook

    by Larry H. Bernstein and Demet Sag
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)

    Jun 20, 2013 | Kindle eBook

    by Margaret Baker PhD and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)

    Aug 10, 2015 | Kindle eBook

    by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)

    Nov 22, 2015 | Kindle eBook

    by Sudipta Saha PhD and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)

    Jul 21, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Prabodah Kandala PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)

    Dec 26, 2015 | Kindle eBook

    by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

    Dec 26, 2015 | Kindle eBook

    by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC
  • Product Details

    Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation

    Nov 29, 2015 | Kindle eBook

    by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RN
    Subscribers read for free.
    Auto-delivered wirelessly
    Sold by: Amazon Digital Services LLC

Forthcoming e-Books in 2017 & 2018

https://pharmaceuticalintelligence.com/biomed-e-books/

 

 

Analytics for the BioMed e-Series based on:

  1. Number of Articles per Volume
  2. E-Readers per Article
  3. Volume e-Impression since DATE of Publication [Summation of 2, above for all articles inside each Volume, before it was inside an e-Book and after the DATE of publication [Product details per Volume in attachment – Five e-Series – several Volumes per e-Series]

PENDING

 

Part 4: Real Time Coverage of 50 Biotech Top Conferences

https://pharmaceuticalintelligence.com/press-coverage/

 

Advertisements

Read Full Post »


Ultra-Pure Melatonin Product Helps Maintain Sleep for Up to 7 Hours

Curator: Gail S. Thornton, M.A.

Co-Editor: The VOICES of Patients, Hospital CEOs, HealthCare Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

 

The role of melatonin is important in regulating natural sleep and wake cycles. Typically, melatonin levels decline with age, significantly decreasing after age 40. An estimated 50 to 70 million Americans are affected by sleep difficulties – a process regulated by melatonin — and long-term sleep deprivation has been associated with negative health consequences, including an increased risk of diabetes, hypertension, heart attack, stroke, obesity, and depression.

Clinical data from a new pharmacokinetic study suggests that REMfresh®, the first and only continuous release and absorption melatonin (CRA-melatonin), helps maintain sleep for up to 7 hours. REMfresh® contains 99 percent ultra-pure melatonin and is sourced in Western Europe, a factor that is significant and important to many sleep specialists.

Three research abstracts on the REMfresh® data were published in an online supplement in the journal, Sleep, and were presented recently at the 31st Annual Meeting of the Associated Professional Sleep Societies LLC (APSS).

REMfresh Photo

Image SOURCE: Photograph courtesy of Physician’s Seal®

How REMfresh® Works

REMfresh® (CRA-melatonin) mimics the body’s own 7-hour Mesa Wave™, a natural pattern of melatonin blood levels during a normal night’s sleep cycle.

The study demonstrated the continuous release and absorption of 99 percent ultra-pure melatonin in REMfresh® (CRA-melatonin) was designed to induce sleep onset and provide continuous, lasting restorative sleep over 7 hours.

The scientifically advanced, patented formulation, called Ion Powered Pump (IPP™) technology, replicates the way in which the body naturally releases and absorbs melatonin, unlike conventional melatonin sleep products.

Since REMfresh® (CRA-melatonin) is not a drug, there is no drug hangover.

REMfresh MesaCurveNew-1

Image SOURCE: Diagram courtesy of Physician’s Seal®

 

Data Based on Scientifically Advanced Delivery Technology

According to the primary study author, David C. Brodner, M.D., “These study results represent an unparalleled breakthrough in drug-free, sleep maintenance that physicians and patients have been waiting for in a sleep product.” Dr. Brodner is a sleep specialist who is double board-certified in Otolaryngology – Head and Neck Surgery and Sleep Medicine and is the founder and principle physician at the Center for Sinus, Allergy, and Sleep Wellness in Palm Beach County, Florida.

Dr. Brodner said, “Melatonin products have been used primarily as a chronobiotic to address sleep disorders, such as jet lag and shift work. The patented delivery system in REMfresh mimics the body’s own natural sleep pattern, so individuals may experience consistent, restorative sleep and have an improved quality of life with this drug-free product.”

Study Findings With REMAKT

The study findings are based on REMAKT™ (REM Absorption Kinetics Trial), a U.S.-based randomized, crossover pharmacokinetic (PK) evaluation study in healthy, non-smoking adults that compared REMfresh® (CRA-melatonin) with a market-leading, immediate-release melatonin (IR-melatonin).

The study found that melatonin levels with REMfresh® exceeded the targeted sleep maintenance threshold for a median of 6.7 hours, compared with 3.7 hours with the leading IR-melatonin. Conversely, the levels of the market-leading IR-melatonin formulation dramatically increased 23 times greater than the targeted levels of exogenous melatonin for sleep maintenance and had a rapid decline in serum levels that did not allow melatonin levels to be maintained beyond 4 hours.

Additional analysis presented showed that REMfresh® (CRA-melatonin) builds upon the body of evidence from prolonged-release melatonin (PR-M), which demonstrated in well-conducted, placebo-controlled studies, statistically significant improvement in sleep quality, morning alertness, sleep latency and quality of life in patients aged 55 years and older compared with placebo.

REMfresh® (CRA-melatonin) was designed to overcome the challenges of absorption in the intestines, thereby extending the continual and gradual release pattern of melatonin through the night (known as the Mesa Wave™, a flat-topped hill with steep sides). There was a faster time to Cmax, which is anticipated to result in improved sleep onset, while the extended median plateau time to 6.7 hours and rapid fall-off in plasma levels at the end of the Mesa Wave™ may help to improve sleep maintenance and morning alertness.

REFERENCE/SOURCE

Physician’s Seal® and REMfresh® (www.remfresh.com)

REMfresh® press release, June 5, 2017 (http://www.prnewswire.com/news-releases/scientifically-advanced-delivery-technology-in-sleep-management-debuts-at-sleep-2017-with-clinical-data-showing-remfresh-the-first-and-only-continuous-release-and-absorption-melatonin-helps-maintain-sleep-for-up-to-7-hours-300468218.html)

Dr. David C. Brodner, Center for Sinus, Allergy, and Sleep Wellness  (http://www.brodnermd.com/sleep-hygiene.html)

Other related articles published in this Open Access Online Scientific Journal include the following:

2017

Sleep Research Society announces 2017 award recipients including Thomas S. Kilduff, PhD, Director, Center for Neuroscience at SRI International in Menlo Park, California

https://pharmaceuticalintelligence.com/2017/04/28/sleep-research-society-announces-2017-award-recipients-including-thomas-s-kilduff-phd-director-center-for-neuroscience-at-sri-international-in-menlo-park-california/

2016

Sleep Science

Genetic link to sleep and mood disorders

https://pharmaceuticalintelligence.com/2016/02/27/genetic-link-to-sleep-and-mood-disorders/

2015

Sleep quality, amyloid and cognitive decline

https://pharmaceuticalintelligence.com/2015/10/31/sleep-quality-amyloid-and-cognitive-decline/

2013

Day and Night Variation in Melatonin Level affects Plasma Membrane Redox System in Red Blood Cells

https://pharmaceuticalintelligence.com/2013/02/23/httpwww-ncbi-nlm-nih-govpubmed22561555/

Read Full Post »


Who are the TOP Referrers for pharmaceuticalintelligence.com?

Reporter: Aviva Lev-Ari, PhD, RN

Referrers for all days ending 2017-05-09 (Summarized

 

All Time

Referrer Views
Search Engines   622,331
linkedin.com 24,335
Facebook 6,955
lnkd.in 6,267
scholar.google.com 3,657
Twitter 3,108
investorshub.advfn.com 1,036
android-app 949
WordPress Dashboard 908
scoop.it 803
mail.yahoo.com 765
scholar.google.co.in 485
scholar.google.co.uk 453
avanza.se 401
WordPress.com Reader 394
correio.portugalmail.pt/imp/ 381
36ohk6dgmcd1n-c.c.yom.mail.yahoo.net 348
scholar.google.co.jp 296
scholar.google.de 260
wcvb.com 249
feedly.com 246
Google+ 234
scholar.google.ca 231
touch.www.linkedin.com 195
scholar.google.com.au 187
coursewareobjects.elsevier.com/objects/McCance7e/mod08b/08s01l0113.html 162
scholar.google.fr 153
bioportfolio.com 145
synergyhealthconcepts.com/tvam-transvascular-autonomic-modulation/ 143
quetext.com 135
scholar.google.es 131
web.mail.comcast.net 128
scholar.google.nl 128
en.wikipedia.org 126
scholar.google.com.br 119
scholar.google.it 116
Google 115
delta-search.com 113
sp.astellasonline.net 109
lse.co.uk 105
scholar.google.com.pk 103

Read Full Post »


Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Editor-in-Chief http://pharmaceuticalintelligence.comAviva Lev-Ari, PhD, RN

We have identified the following FIVE Innovations and provide Case Studies to demonstrate these statements.

Innovation #1:

Methodology of Expert Curation of Scientific Findings is applied in all the articles that are included in LPBI Group’s 16 e-Books

Innovation #2:

The Journal Archive by Month is sorted by Categories of Research that can serve multiple Goals in eScientific Publishing

Innovation #3:

Marketing of electronic Scientific Contents – eReaders’ Views Analytics: Site Statistics, Top Article Views, Top Author’s Views

Innovation #4:

Cross section of several Categories of Research supports interdisciplinary conceptual innovations – it is evidence that knowledge is in SILOS to a great degree, still.

Innovation #5:

Real Time Press coverage of Scientific Conferences Builds exposure to FRONTIER of Science that guides CONTENT creation in the Journal and in the BioMed e-Series

 

Case Studies for Innovations #1, #2, #3, #4, #5

 

Innovation #1:

1.1  Methodology of Expert Curation of Scientific Findings is applied in all the articles that are included in LPBI Group’s 16 e-Books

Editorial & Publication of Articles in e-Books by  Leaders in Pharmaceutical Business Intelligence:  Contributions of Larry H Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence:  Contributions of Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/founder/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence/

1.2  The Methodology of Expert Curation of Scientific Findings deserves the status of an eScientific Publishing Class, in its own right – Our 5100 articles demonstrate that capability and virtue

http://pharmaceuticalintelligence.com

  • Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

Innovation #2:

The Journal Archive by Month is sorted by Categories of Research that can serve multiple Goals in eScientific Publishing:

 

2.1  Repository for generation of electronic Table of Contents (eTOCs) used in creation of electronic Books (eBooks).

Examples include our BioMed e-Series:

Forthcoming SEVEN e-Books in 2017/18 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

BioMed e-Series

https://pharmaceuticalintelligence.com/biomed-e-books/

BioMed e-Series

WE ARE ON AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_ss_i_1_15?url=search-alias%3Dstripbooks&field-keywords=aviva+lev-ari+phd+rn&sprefix=%22Aviva+Lev-Ari%2C%2Caps%2C129&crid=3V1F20IV5LHE3

2.2  Categories of Research serves as Ontologies for Journals

Examples. include our Open Access Online Scientific Journal

http://pharmaceuticalintelligence.com

Our DOMAINS in Scientific Media

I.  Pharmaceutical: Biologics, Small Molecules, Diagnostics

II.  Life Sciences: Genomics and Cancer Biology

III.  Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology: Metabolomics, Immunology

IV. Biomedicine, BioTech, and MedTech (Medical Devices)

V.  HealthCare: Patient-centered Medicine and Personalized/Precision Medicine

Innovation #3:

Marketing of electronic Scientific Contents – eReaders’ Views Analytics: Site Statistics, Top Article Views, Top Author’s Views

 

3.1 Site Statistics on 5/5/52017

1,208,981 Views – all articles [not only articles with e-Views >1,000 = 445,321]

7,267 Scientific Comments

5,096 articles

9,566 tags

578 Categories of Research

3.2 FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by

e-Views >1,000, 4/27/2012 to 4/27/2017

Article Title

 

Views All Time

Author

Home page / Archives

445,321

e-Readers

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

15,461

Larry H. Bernstein, MD, FCAP

Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

10,005

 

Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

3.3  Top Authors, by 5 years of e-Views, 4/25/2017, on pharmaceuticalintelligence.com 

4/30/2012 – 4/25/2017 (All Times – Summarized)

Author

Views

Aviva Lev-Ari, PhD, RN

315,262

 

Larry H Bernnstein, MD, FCAP

220,787

Tilda Barliya, PhD

47,008

 

Stephen J Williams, PhD

39,704

Dror Nir, PhD

24,484

Sudipta Saha, PhD

22,253

Ritu Saxena, PhD

15,302

Demet Sag, Ph.D., CRA, GCP

12,982

Aviral Vatsa, PhD

8,082

Ziv Raviv, PhD

7,525

Zohi Sternberg, PhD

3,839

Anamika Sarkar, PhD, MBA

3,269

Gail S Thornton, MA, PhD(c)

2,885

Danut Dragoi, PhD

2,607

Prabodh Kandala, PhD

2,115

Alan F. Kaul, PharmD., MS, MBA, FCCP

2,057

Aashir Awan, PhD

1,841

Meg Baker, PhD

1,439

Justin D Pearlman, MD, PhD

1,429

https://pharmaceuticalintelligence.com/2017/04/25/top-authors-by-5-years-of-e-views-4252017-on-pharmaceuticalintelligence-com/

Innovation #4:

Cross section of several Categories of Research supports interdisciplinary conceptual innovations – it is evidence that knowledge is in SILOS to a great degree, still.

 

Examples for interdisciplinary conceptual innovations include:

  • Dr. Aviva Lev-Ari‘s early curations represent an intersection of Vascular Biology and Molecular Cardiology – that has yielded a Novel Combination Drug Therapy Concept in cardiovascular diseases.

Cardiovascular Diseases and Pharmacological Therapy: Curations

 

  • Dr. Larry H. Bernstein, MD, FCAP curations in Enzymology and Pathophysiology

ATP – the universal energy carrier in the living cell: Reflections on the discoveries and applications in Medicine

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

 

Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics

Editor: Larry H. Bernstein, MD, FCAP

http://www.amazon.com/dp/B019VH97LU

Cyclic Dinucleotides and Histone deacetylase inhibitors

Curators: Larry H. Bernsten, MD, FCAP and Aviva Lev-Ari, PhD, RN

 

  • Dr. Stephen J. Williams curations in Pharmacology and Oncology

Why Does Cytotoxic Chemotherapy Still Remain a Mainstay in Many Chemotherapy Regimens

New Generation of Platinated Compounds to Circumvent Resistance

New Topoisomerase Inhibitors: Agents From Nature

Are Cyclin D Inhibitors a Good Target?

 

  • Dr. Dror Nir’s curations in Medical Imaging and Oncology

Imaging Technology in Cancer Surgery

Metastatic Diseases – Examples of Surgical Procedures in Treatment of Cancer

Ablation Techniques in Interventional Oncology

 

  • Dr. Tilda Barliya’s curations in Nanotechnology, Molecular Biology and Drug Delivery

Building a Drug-Delivery System (DDS): choice of polymers and drugs

Factors affecting the PK of the nanocarrier

Detection and Imaging

Single-Molecule Detection by Philip Tinnefeld

Mesothelin: An early detection biomarker for cancer (By Jack Andraka)

Nanotechnology and MRI imaging

Nanotechnology: Detecting and Treating metastatic cancer in the lymph node

Diagnosing lung cancer in exhaled breath using gold nanoparticles

Innovation #5:

Real Time Press coverage of Scientific Conferences Builds exposure to FRONTIER of Science that guides CONTENTS creation in the Journal and in the BioMed e-Series

 

5.1 Press Coverage of BioTech, Medicine and Life Sciences Conferences, 2013 – 2017

https://pharmaceuticalintelligence.com/press-coverage/

List of Conferences in 2017

The 13th Annual Personalized Medicine Conference, NOVEMBER 14 – 16, 2017, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston

https://pharmaceuticalintelligence.com/2017/03/13/the-13th-annual-personalized-medicine-conference-from-concept-to-the-clinic-november-14-16-2017-joseph-b-martin-conference-center-harvard-medical-school-77-avenue-louis-pasteur-boston/

 

16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 2017, 9AM – 5PM, Kresge Auditorium, MIT

https://pharmaceuticalintelligence.com/2017/03/13/16th-annual-cancer-research-symposium-koch-institute-friday-june-16-9am-5pm-kresge-auditorium-mit/

 

BioInformatics: Track 6: BioIT World Conference & Expo ’17, May 23-25, 2017, Seaport World Trade Center, Boston, MA

https://pharmaceuticalintelligence.com/2017/01/12/2017-agenda-bioinformatics-track-6-bioit-world-conference-expo-17-may-23-35-2017-seaport-world-trade-center-boston-ma/

 

2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston

https://pharmaceuticalintelligence.com/2016/12/14/2017-world-medical-innovation-forum-cardiovascular-may-1-3-2017-partners-healthcare-boston-at-the-westin-hotel-boston/

 

2017 MassBio Annual Meeting March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA

https://pharmaceuticalintelligence.com/2017/02/28/2017-massbio-annual-meeting-march-30-2017-800-am-march-31-2017-400-pm-royal-sonesta-boston-cambridge-ma/

 

5.2  eProceedings generated in Real Time, Social Media facilitate Global e-Readers Reach and instantaneous reach of conference attendees 

  • World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(a) Real Time Highlights and Tweets: Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(b) e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(c)  Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

 

5.3 Opportunities for Import of Innovations from Conferences to the Journal and to the BioMed e-Series

From World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care

 

12. Aging and Heart Disease: Can we reverse the process?

11.Nanotechnologies for Cardiac Diagnosis and Treatment

10. Breaking the Code: Diagnosis and Therapeutic Potential of RNA

9. Expanding the Pool of Organs for Transplant

8. Finding Cancer therapies without Cardiotoxicity

7. Less is more: Minimalist Mitral Valve Repair

6. Understanding Why exercise works for Just about every thing

5. Power Play: The Future of Implantable Cardiac Devices

4. Adopting the Orphan of Heart Disease

3. Targeting Inflammation in cardiovascular Disease

2. Harnessing Big Data and Deep Learning for Clinical Decision Support

  1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

Read Full Post »


FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com,

Top Articles by Author and by e-Views >1,000,

4/27/2012 to 4/27/2017

 

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

 

FIVE years of e-Scientific Publishing  –  Top Articles by e-Views >1,000 for all days ending 2017-04-27 (Summarized)

@pharmaceuticalintellicence.com

 
Article Title
  Views All Time Author

Home page / Archives

445,321

e-Readers

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? 15,461 Larry H. Bernstein, MD, FCAP
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 10,005  

Vivek Lal, MBBS, MD, FCIR, Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN

Recent comprehensive review on the role of ultrasound in breast cancer management 7,513 Dror Nir, PhD
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 6,721 Tilda Barliya, PhD
Our TEAM 5,722 Aviva Lev-Ari, PhD, RN
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 5,380 Tilda Barliya, PhD
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 4,379 Aviva Lev-Ari, PhD, RN
Akt inhibition for cancer treatment, where do we stand today? 4,077 Ziv Raviv, PhD
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 3,847 Zohi Sternberg, PhD
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 3,609 Aviva Lev-Ari, PhD, RN
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms 3,456 Larry H. Bernstein, MD, FCAP, Stephen J Williams, PhD, Aviral Vatsa, PhD, et al.
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad 3,330 Demet Sag, PhD
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo 3,215 Stephen J Williams, PhD
Founder 3,131 Aviva Lev-Ari, PhD, RN
BioMed e-Series 3,005 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN,

et al.

Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology 2,866 Tilda Barliya, PhD
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 2,854 Larry H. Bernstein, MD, FCAP, Justin D. Pearlman, MD, PhD and Aviva Lev-Ari, PhD, RN
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I 2,677 Larry H. Bernstein, MD, FCAP
VISION 2,651 Aviva Lev-Ari, PhD, RN
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community 2,602 Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Funding, Deals & Partnerships 2,506 Aviva Lev-Ari, PhD, RN
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 2,461 Stephen J Williams, PhD
Bone regeneration and nanotechnology 2,446 Tilda Barliya, PhD
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging 2,400 Dror Nir, PhD
“The Molecular pathology of Breast Cancer Progression” 2,315 Tilda Barliya, PhD
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation 2,240 Larry H. Bernstein, MD, FCAP
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) 2,190 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Targeting the Wnt Pathway [7.11] 2,162 Larry H. Bernstein, MD, FCAP
In focus: Circulating Tumor Cells 2,151 Ritu Saxena, PhD
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) 2,110 Justin D. Pearlman, MD, PhD, FACC, Larry H. Bernstein, MD, FCAP
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 2,100 Stephen J Williams, PhD
Journal PharmaceuticalIntelligence.com 2,068 Aviva Lev-Ari, PhD, RN and  et al.
About 2,044 Aviva Lev-Ari, PhD, RN
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment 2,028 Sudipta Saha, PhD
Interaction of enzymes and hormones 1,994 Larry H. Bernstein, MD, FCAP
Problems of vegetarianism
1,908 Sudipta Saha, PhD
DNA Structure and Oligonucleotides 1,905 Larry H. Bernstein, MD, FCAP
Biosimilars: CMC Issues and Regulatory Requirements 1,813 Aviva Lev-Ari, PhD, RN
CD47: Target Therapy for Cancer 1,763 Tilda Barliya, PhD
Lipid Metabolism 1,761 Larry H. Bernstein, MD, FCAP
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes 1,761 Aviva Lev-Ari, PhD, RN
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG) 1,725 Tilda Barliya, PhD
Non-small Cell Lung Cancer drugs – where does the Future lie? 1,720 Ritu Saxena, PhD
A Primer on DNA and DNA Replication 1,720 Larry H. Bernstein, MD, FCAP
Introduction to Tissue Engineering; Nanotechnology applications 1,711 Tilda Barliya, PhD
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node 1,667 Tilda Barliya, PhD
Nitric Oxide Function in Coagulation – Part II 1,614 Larry H. Bernstein, MD, FCAP
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research 1,603 Stephen J Williams, PhD
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® 1,578 Aviva Lev-Ari, PhD, RN
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB 1,542 Aviva Lev-Ari, PhD, RN
The role of biomarkers in the diagnosis of sepsis and patient management 1,500 Larry H. Bernstein, MD, FCAP
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers 1,475 Aviva Lev-Ari, PhD, RN
Nanotechnology and MRI imaging 1,470 Tilda Barliya, PhD
Baby’s microbiome changing due to caesarean birth and formula feeding 1,457 Aviva Lev-Ari, PhD, RN
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions 1,453 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays 1,424 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? 1,417 Aviva Lev-Ari, PhD, RN
Neonatal Pathophysiology 1,412 Larry H. Bernstein, MD, FCAP
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) 1,408 Aviva Lev-Ari, PhD, RN
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases 1,396 Justin D. Pearlman, MD, PhD, FACC
IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase 1,384 Demet Sag, PhD
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack 1,360 Aviva Lev-Ari, PhD, RN
Monoclonal Antibody Therapy and Market 1,352 Demet Sag, PhD
Mitochondrial Damage and Repair under Oxidative Stress 1,315 Larry H. Bernstein, MD, FCAP
Closing the Mammography gap 1,292 Dror Nir, PhD
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease 1,288 Aviva Lev-Ari, PhD, RN
Update on FDA Policy Regarding 3D Bioprinted Material 1,286 Aviva Lev-Ari, PhD, RN
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? 1,276 Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Aviva Lev-Ari, PhD, RN, Director and Founder 1,250 Aviva Lev-Ari, PhD, RN
Diagnostic Evaluation of SIRS by Immature Granulocytes 1,249 Larry H. Bernstein, MD, FCAP
Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) 1,238 Larry H. Bernstein, MD, FCAP
Signaling and Signaling Pathways 1,235 Larry H. Bernstein, MD, FCAP
Crucial role of Nitric Oxide in Cancer 1,215 Ritu Saxena, PhD
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes 1,211 Aviva Lev-Ari, PhD, RN
Mitochondrial fission and fusion: potential therapeutic targets? 1,203 Ritu Saxena, PhD
Diet and Diabetes 1,186 Larry H. Bernstein, MD, FCAP
Mitochondrial Dynamics and Cardiovascular Diseases 1,171 Ritu Saxena, PhD
Nanotechnology and Heart Disease 1,159 Tilda Barliya, PhD
Nitric Oxide and Immune Responses: Part 2 1,153 Aviral Vatsa, PhD
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery 1,153 Aviva Lev-Ari, PhD, RN
The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments 1,149 Larry H. Bernstein, MD, FCAP
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly 1,128 Aviva Lev-Ari, PhD, RN
Scientific and Medical Affairs Chronological CV 1,127 Aviva Lev-Ari, PhD, RN
Assessing Cardiovascular Disease with Biomarkers 1,122 Larry H. Bernstein, MD, FCAP
Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing 1,116 Stephen J Williams, PhD
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors 1,112 Stephen J Williams, PhD
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function 1,111 Larry H. Bernstein, MD, FCAP
Nanotechnology and HIV/AIDS treatment 1,109 Tilda Barliya, PhD
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin 1,107 Aviva Lev-Ari, PhD, RN
Ultrasound-based Screening for Ovarian Cancer 1,105 Dror Nir, PhD
Stenting for Proximal LAD Lesions 1,082 Aviva Lev-Ari, PhD, RN
Treatment of Refractory Hypertension via Percutaneous Renal Denervation 1,082 Aviva Lev-Ari, PhD, RN
Nitric Oxide and it’s impact on Cardiothoracic Surgery 1,079 Tilda Barliya, PhD
Wnt/β-catenin Signaling [7.10] 1,078 Larry H. Bernstein, MD, FCAP
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism 1,068 Larry H. Bernstein, MD, FCAP,             Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands 1,063 Aviva Lev-Ari, PhD, RN
Patiromer – New drug for Hyperkalemia 1,054 Aviva Lev-Ari, PhD, RN
Isoenzymes in cell metabolic pathways 1,048 Larry H. Bernstein, MD, FCAP
Sex Hormones 1,039 Larry H. Bernstein, MD, FCAP
LPBI Group 1,027 Aviva Lev-Ari, PhD, RN
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty 1,027 Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I 1,020 Aviral Vatsa, PhD
Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents 1,015 Aviral Vatsa, PhD
Ovarian Cancer and fluorescence-guided surgery: A report 1,012 Tilda Barliya, PhD
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation 1,012 Aviva Lev-Ari, PhD, RN
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model 1,011 Anamika Sarkar, PhD
New England Compounding Center: A Family Business 1,008 Alan F. Kaul, PharmD
Integrins, Cadherins, Signaling and the Cytoskeleton 1,003 Larry H. Bernstein, MD, FCAP

Read Full Post »


Top Authors, by 5 years of e-Views, 4/25/2017, on pharmaceuticalintelligence.com

Reporter: Aviva Lev-Ari, PhD, RN

 

Top Authors for all days ending 2017-04-25 (Summarized)

All Time

4/30/2012 – 4/25/2017

Author

Views

Aviva Lev-Ari, PhD, RN 315,262
 

Larry H Bernnstein, MD, FCAP
220,787
Tilda Barliya, PhD 47,008
 

Stephen J Williams, PhD
39,704
Dror Nir, PhD
24,484
Sudipta Saha, PhD
22,253
Ritu Saxena, PhD
15,302
Demet Sag, Ph.D., CRA, GCP
12,982
Aviral Vatsa, PhD
8,082
Ziv Raviv, PhD
7,525
Zohi Sternberg, PhD
3,839
Anamika Sarkar, PhD, MBA
3,269
Gail S Thornton, MA, PhD(c)
2,885
Danut Dragoi, PhD
2,607
Prabodh Kandala, PhD
2,115
Alan F. Kaul, PharmD., MS, MBA, FCCP
2,057
Aashir Awan, PhD
1,841
Meg Baker, PhD
1,439
Justin D Pearlman, MD, PhD
1,429
Irina Robu, PhD
949
S. Chakrabarti, Ph.D. 622

 

 

Read Full Post »


We celebrate 5,070 Scientific Articles – pharmaceuticalintelligence.com –

Top Posts with Greater than 2,000 Views

 

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

 

Website Statistics on April 12, 2017, 3:09 PM – All time

 

1,193,720 views

7,267 comments

 

Content

5,070 Scientific Articles

572 Categories

9,557 Tags

 

Referrers for all days ending 2017-04-12 (Summarized)

All Time

Referrer Views
Search Engines 609,953
linkedin.com 24,279
Facebook 6,905
lnkd.in 6,262
scholar.google.com 3,565
Twitter 3,093
investorshub.advfn.com 1,072
WordPress Dashboard 902
android-app 862
scoop.it 802
mail.yahoo.com 765
scholar.google.co.in 473
scholar.google.co.uk 438
 

 

Clicks for all days ending 2017-04-12 (Summarized)

URL Clicks
WordPress.com Media 30,683
commons.wikipedia.org 6,013
http://www.ncbi.nlm.nih.gov 3,652
en.wikipedia.org 3,151
http://www.nature.com 2,565
dx.doi.org 1,309
http://www.scoop.it 970
pharmaceuticalintelligence.wordpress.com 736
http://www.sciencedirect.com 654
gravatar.com 627
http://www.fda.gov 519
apps.societyforscience.org/intelisef2012/project.cfm?PID=ME028&CFID=28485&CFTOKEN=10931553 514
http://www.cancer.gov 419
http://www.medscape.com 384

 

Top Posts with Greater than 2,000 Views for all days ending 2017-04-12 (Summarized)

 

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View?

15,394
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) 9,916
Recent comprehensive review on the role of ultrasound in breast cancer management 7,426
Paclitaxel vs Abraxane (albumin-bound paclitaxel) 6,594
Our TEAM 5,708
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) 5,349
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care 4,272
Akt inhibition for cancer treatment, where do we stand today? 4,047
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses 3,829
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications 3,536
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms 3,452
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad 3,318
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo 3,207
Founder 3,128
BioMed e-Series 3,000
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology 2,852
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets 2,845
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) 2,830
VISION 2,638
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I 2,636
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community 2,595
Funding, Deals & Partnerships 2,500
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules 2,439
Bone regeneration and nanotechnology 2,425
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging 2,382
“The Molecular pathology of Breast Cancer Progression” 2,307
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) 2,175
In focus: Circulating Tumor Cells 2,147
Targeting the Wnt Pathway [7.11] 2,143
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) 2,103
Journal PharmaceuticalIntelligence.com 2,062
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation 2,046
About 2,043
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment 2,008
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation 2,008

 

Read Full Post »

Older Posts »